Elaine Castellanos net worth and biography

Elaine Castellanos Biography and Net Worth

Elaine is Senior Vice President, Chief Accounting Officer at Reata Pharmaceuticals and oversees financial accounting and reporting, ensuring company accounting procedures and reporting conform to generally accepted accounting principles. She joined Reata in 2008 and has over 25 years of financial accounting and reporting experience.

Prior to joining Reata, Elaine was previously a Senior Manager in the health sciences group at Ernst & Young, with clients ranging from non-profits and development-stage companies to the Fortune 500. Elaine received a B.A. in Economics and Managerial Studies and a Masters of Accounting from Rice University. She is also a Certified Public Accountant.

What is Elaine Castellanos' net worth?: The estimated net worth of Elaine Castellanos is at least $2.77 million as of June 7th, 2021. Ms. Castellanos owns 16,092 shares of Reata Pharmaceuticals stock worth more than $2,773,617 as of April 3rd. This net worth estimate does not reflect any other investments that Ms. Castellanos may own. Learn More about Elaine Castellanos' net worth.
How do I contact Elaine Castellanos?: The corporate mailing address for Ms. Castellanos and other Reata Pharmaceuticals executives is 5320 LEGACY DRIVE, PLANO TX, 75024. Reata Pharmaceuticals can also be reached via phone at (972) 865-2219 and via email at ir@reatapharma.com. Learn More on Elaine Castellanos' contact information.
Has Elaine Castellanos been buying or selling shares of Reata Pharmaceuticals?: Elaine Castellanos has not been actively trading shares of Reata Pharmaceuticals during the last ninety days. Most recently, Elaine Castellanos sold 8,454 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $141.90, for a transaction totalling $1,199,622.60. Following the completion of the sale, the chief accounting officer now directly owns 16,092 shares of the company's stock, valued at $2,283,454.80. Learn More on Elaine Castellanos' trading history.
Who are Reata Pharmaceuticals' active insiders?: Reata Pharmaceuticals' insider roster includes Bhaskar Anand (CAO), Dawn Bir (Chief Commercial Officer), Elaine Castellanos (CAO), Samina Khan (SVP), Andrea Loewen (SVP), Colin Meyer (Insider), Shamim Ruff (Director), Manmeet Soni (CFO), and Michael Wortley (Insider). Learn More on Reata Pharmaceuticals' active insiders.

Elaine Castellanos Insider Trading History at Reata Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/9/2021	Sell	8,454	$141.90	$1,199,622.60	16,092
6/7/2021	Sell	1,546	$146.75	$226,875.50	16,092
5/26/2021	Sell	10,000	$124.55	$1,245,500.00	24,546
6/1/2020	Sell	2,000	$143.97	$287,940.00	17,146
3/2/2020	Sell	2,000	$194.32	$388,640.00	17,146
12/2/2019	Sell	2,000	$194.24	$388,480.00	17,146
10/28/2019	Sell	4,000	$200.00	$800,000.00	19,146
10/25/2019	Sell	2,000	$190.00	$380,000.00	15,146
10/18/2019	Sell	2,000	$170.00	$340,000.00	13,933
10/14/2019	Sell	3,000	$105.00	$315,000.00	11,933
9/6/2019	Sell	2,000	$85.00	$170,000.00	4,138
6/3/2019	Sell	2,000	$85.20	$170,400.00	4,138
4/8/2019	Sell	2,000	$90.17	$180,340.00	4,138
3/5/2019	Sell	3,588	$102.00	$365,976.00	5,726
7/23/2018	Sell	7,336	$50.81	$372,742.16	140

See Full Table

Elaine Castellanos Buying and Selling Activity at Reata Pharmaceuticals

Reata Pharmaceuticals Company Overview

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Today's Range

Now: $172.36

$172.32

$172.46

50 Day Range

MA: $171.30

$168.70

$172.36

2 Week Range

Now: $172.36

$21.83

$172.46

Volume

1,988,500 shs

Average Volume

1,091,032 shs

Market Capitalization

$6.58 billion

P/E Ratio

N/A

Dividend Yield